Whalesbook
Strong Operations and Expansion Plans
Vikram Solar concluded fiscal year 2026 with strong operational results, reporting approximately 971MW of module production and about 999MW in sales for Q4 FY26. The company's order book stood at 8.2 GW on March 31, 2026, with Independent Power Producers (IPPs) making up 69% of this backlog. Capacity utilization averaged 75% for the fiscal year. The company is pursuing significant backward integration. A 6 GW module facility in Gangaikondan is slated for commissioning by June 2026, which will raise total module capacity to 15.5 GW. Further expansion includes a 9 GW TOPCon cell facility aiming for initial production from December 2026 and a 6 GW wafer/ingot facility at Gangaikondan, requiring an investment of roughly ₹3,726 crore by FY29. This push aims to reduce supply chain risks and capture more value in solar manufacturing.
Valuation, Peers, and Financials
Vikram Solar has a market capitalization of about ₹7,700-7,800 crore. Its trailing twelve-month (TTM) Price-to-Earnings (P/E) ratio is around 15.79x-17.96x, with a forward P/E of approximately 13.67x. Compared to peers in the solar manufacturing sector, Vikram Solar's valuation metrics are mixed. Waaree Energies has a higher TTM P/E of about 31.3x as of May 2026, while Waaree Renewable Technologies trades at roughly 22.23x. Vikram Solar's P/E is lower than the sector median P/E of 33.9x for comparable IT sector companies. The company's Debt-to-Equity ratio is a conservative 0.20, showing sound financial management.
Margin Pressure and Analyst Concerns
Despite strong revenue growth and expansion plans, margin compression is a key concern. Vikram Solar's operating margin fell to 16.14% in Q4 FY26 from 17.87% a year earlier, though absolute EBITDA increased. This trend, along with industry overcapacity and the time needed to bring new facilities online, has led to a more cautious analyst view. Prabhudas Lilladher downgraded Vikram Solar to 'Accumulate' from 'Buy', cutting its target price to ₹226 from ₹326. This downgrade reflects concerns about stabilizing new cell operations and potential near-term challenges from industry oversupply. Other analysts, however, maintain 'Buy' ratings with average 12-month targets around ₹240-254, indicating mixed market sentiment. Investors also face unresolved issues like ₹201 crore in disputed receivables and withheld payments. The company's stock has been volatile, trading near its 52-week low and down about 9.79% year-to-date.
Outlook and Investor Considerations
Analysts forecast revenue and EBITDA to grow annually by 60-70% between FY26-28, driven by new capacity and a strong order pipeline. The company's focus on backward integration should improve cost efficiencies and reduce supply chain volatility long-term. However, the near-term outlook depends on successfully launching new facilities, managing industry overcapacity, and halting margin declines. While many analysts remain positive with price targets suggesting upside, the 'Accumulate' rating from Prabhudas Lilladher, alongside the company's expansion and sector risks, indicates a path that may involve continued volatility and requires a patient investor.